MyFinsight
Home
Blog
About
Revenues
$628,690K
(10.63%↑ Y/Y)
Interest income
$14,210K
(-15.36%↓ Y/Y)
Net income
$212,050K
(14.72%↑ Y/Y)
Prepaid expenses and
other assets
-$40,503K
(-138.68%↓ Y/Y)
Stock-based compensation
$32,563K
(-9.73%↓ Y/Y)
Acquired in-process
research and development...
$8,575K
(1043.33%↑ Y/Y)
Depreciation and
amortization
$6,984K
(-4.88%↓ Y/Y)
Trade receivables,
net
-$6,734K
(-162.83%↓ Y/Y)
Non-cash lease expense
$5,927K
(-2.36%↓ Y/Y)
Proceeds from maturities
and sales of...
$169,268K
(-52.06%↓ Y/Y)
Canceled cashflow
$430,850K
Accounts payable and
other liabilities
$5,031K
(107.92%↑ Y/Y)
Net cash provided by
operating activities
$307,741K
(528.13%↑ Y/Y)
Net cash provided by
investing activities
$91,430K
(-63.14%↓ Y/Y)
Canceled cashflow
$10,626K
Canceled cashflow
$77,838K
Development
$150,522K
(12.20%↑ Y/Y)
Selling, general, and
administrative
$127,413K
(12.82%↑ Y/Y)
Other segment items
$63,378K
(-5.01%↓ Y/Y)
Provision for income taxes
$50,628K
(11.11%↑ Y/Y)
Cost of goods sold
$20,657K
(6.10%↑ Y/Y)
Drug discovery
$18,252K
(-14.54%↓ Y/Y)
Net decrease in cash
and cash...
$55,296K
(386.23%↑ Y/Y)
Canceled cashflow
$343,875K
Accrued collaboration
liabilities
-$9,306K
(-134.76%↓ Y/Y)
Other, net
$1,276K
(-78.12%↓ Y/Y)
Inventory
$44K
(101.67%↑ Y/Y)
Proceeds from issuance of
common stock under the...
$15,440K
(-40.80%↓ Y/Y)
Purchases of marketable
securities
$68,522K
(-32.48%↓ Y/Y)
Purchases of property,
equipment and other, net
$6,816K
(140.17%↑ Y/Y)
Acquired in-process
research and development...
$2,500K
(233.33%↑ Y/Y)
Net cash used in
financing activities
-$343,875K
(-8.70%↓ Y/Y)
Canceled cashflow
$15,440K
Payments for repurchases
of common stock
$322,974K
(6.97%↑ Y/Y)
Taxes paid related to
net share...
$36,341K
(-10.27%↓ Y/Y)
Back
Back
Cash Flow
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
source: myfinsight.com